menu
    • menu
    [{"orgOrder":0,"company":"Radius Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Peptide","year":"2020","type":"Not Applicable","leadProduct":"Abaloparatide Acetate","moa":"PTH1 receptor","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Radius Health","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Trabsdermal Patch","sponsorNew":"Radius Health \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Radius Health \/ Not Applicable"},{"orgOrder":0,"company":"PALADIN LABS","sponsor":"Endo International","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"","productType":"Peptide","year":"2021","type":"Licensing Agreement","leadProduct":"Abaloparatide Acetate","moa":"PTH1 receptor","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"PALADIN LABS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"PALADIN LABS \/ Endo International","highestDevelopmentStatusID":"10","companyTruncated":"PALADIN LABS \/ Endo International"},{"orgOrder":0,"company":"Radius Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Peptide","year":"2021","type":"Not Applicable","leadProduct":"Abaloparatide Acetate","moa":"PTH receptor","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Radius Health","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Radius Health \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Radius Health \/ Not Applicable"},{"orgOrder":0,"company":"Radius Health","sponsor":"Gurnet Point Capital","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"","productType":"Peptide","year":"2022","type":"Acquisition","leadProduct":"Abaloparatide Acetate","moa":"PTH1 receptor","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Radius Health","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","amount2New":0.89000000000000001,"dosageForm":"Injectable\/Injection","sponsorNew":"Radius Health \/ Gurnet Point Capital","highestDevelopmentStatusID":"12","companyTruncated":"Radius Health \/ Gurnet Point Capital"},{"orgOrder":0,"company":"Radius Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Abaloparatide Acetate","moa":"PTH1 receptor","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Radius Health","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Radius Health \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Radius Health \/ Not Applicable"},{"orgOrder":0,"company":"Radius Health","sponsor":"Gurnet Point Capital","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Peptide","year":"2022","type":"Acquisition","leadProduct":"Abaloparatide Acetate","moa":"PTH1 receptor","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Radius Health","amount2":0.89000000000000001,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","amount2New":0.89000000000000001,"dosageForm":"Injectable\/Injection","sponsorNew":"Radius Health \/ Gurnet Point Capital","highestDevelopmentStatusID":"12","companyTruncated":"Radius Health \/ Gurnet Point Capital"},{"orgOrder":0,"company":"Radius Health","sponsor":"Gurnet Point Capital","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"","productType":"Peptide","year":"2022","type":"Acquisition","leadProduct":"Abaloparatide Acetate","moa":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Radius Health","amount2":0.89000000000000001,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","amount2New":0.89000000000000001,"dosageForm":"Injectable\/Injection","sponsorNew":"Radius Health \/ Gurnet Point Capital","highestDevelopmentStatusID":"12","companyTruncated":"Radius Health \/ Gurnet Point Capital"},{"orgOrder":0,"company":"Radius Health","sponsor":"Theramex","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"","productType":"Peptide","year":"2023","type":"Licensing Agreement","leadProduct":"Abaloparatide Acetate","moa":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Radius Health","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Radius Health \/ Theramex","highestDevelopmentStatusID":"12","companyTruncated":"Radius Health \/ Theramex"}]

    Find Clinical Drug Pipeline Developments & Deals for Abaloparatide Acetate

    Menu

    Abaloparatide Acetate

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Radius Health

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Radius Health

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Abaloparatide Acetate

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Approved

                            Sponsor : Theramex

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Theramex Enters Into an Exclusive Licensing Agreement With Radius Health Inc, to Commercialise ELADYNOS® ▼i...

                            Details : Theramex will commercialise and distribute Eladynos (abaloparatide), a novel bone forming agent indicated for the treatment of osteoporosis in postmenopausal women at increased risk of fractures on an exclusive basis in the European Economic Area, UK , A...

                            Brand Name : Eladynos

                            Molecule Type : Peptide

                            Upfront Cash : Undisclosed

                            March 20, 2023

                            Lead Product(s) : Abaloparatide Acetate

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Approved

                            Sponsor : Theramex

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Radius Health

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Radius Health

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Abaloparatide Acetate

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Approved

                            Sponsor : Gurnet Point Capital

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Gurnet Point Capital and Patient Square Capital Complete Their Acquisition of Radius Health, Inc.

                            Details : Radius’ lead product, TYMLOS® (abaloparatide) was launched in the U.S. in 2017 for the treatment of postmenopausal women with osteoporosis at high risk for fracture.

                            Brand Name : Tymlos

                            Molecule Type : Peptide

                            Upfront Cash : Undisclosed

                            August 15, 2022

                            Lead Product(s) : Abaloparatide Acetate

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Approved

                            Sponsor : Gurnet Point Capital

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Radius Health

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Radius Health

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Abaloparatide Acetate

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Approved

                            Sponsor : Gurnet Point Capital

                            Deal Size : $890.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Gurnet Point Capital and Patient Square Capital Complete Their Acquisition of Radius Health, Inc.

                            Details : The acquisition of Radius by Gurnet Point and Patient Square provides our shareholders with attractive, immediate value at a compelling premium, in addition to the potential future upside of TYMLOS (abaloparatide) through the CVR.

                            Brand Name : Tymlos

                            Molecule Type : Peptide

                            Upfront Cash : $547.0 million

                            August 15, 2022

                            Lead Product(s) : Abaloparatide Acetate

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Approved

                            Sponsor : Gurnet Point Capital

                            Deal Size : $890.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Radius Health

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Radius Health

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Abaloparatide Acetate

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Approved

                            Sponsor : Gurnet Point Capital

                            Deal Size : $890.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Radius Health Announces Agreement to be Acquired by Gurnet Point Capital and Patient Square Capital

                            Details : The acquisition of Radius by Gurnet Point and Patient Square provides our shareholders with attractive, immediate value at a compelling premium, in addition to the potential future upside of TYMLOS (abaloparatide) through the CVR.

                            Brand Name : Tymlos

                            Molecule Type : Peptide

                            Upfront Cash : $547.0 million

                            June 23, 2022

                            Lead Product(s) : Abaloparatide Acetate

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Approved

                            Sponsor : Gurnet Point Capital

                            Deal Size : $890.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Radius Health

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Radius Health

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Abaloparatide Acetate

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Radius Health Update on Abaloparatide Transdermal System

                            Details : The data for spine BMD vs. baseline showed abalo-TDS had a 7.1% increase vs. TYMLOS (abaloparatide) +10.9%, both considered clinically meaningful. Despite missing the non-inferiority margin, the transdermal system demonstrated a bone building benefit to ...

                            Brand Name : Tymlos

                            Molecule Type : Peptide

                            Upfront Cash : Not Applicable

                            June 01, 2022

                            Lead Product(s) : Abaloparatide Acetate

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Radius Health

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Radius Health

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Abaloparatide Acetate

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Radius Announces Results from the wearABLe Trial Evaluating Abaloparatide Transdermal System in Postmenopausal...

                            Details : Company announced phase 3 topline results from the wearABLe study did not meet its primary endpoint evaluating the NI of BA058 (abaloparatide) in postmenopausal women with osteoporosis.

                            Brand Name : BA058

                            Molecule Type : Peptide

                            Upfront Cash : Not Applicable

                            December 08, 2021

                            Lead Product(s) : Abaloparatide Acetate

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            PALADIN LABS

                            Canada arrow
                            2024 ACI Convention
                            Not Confirmed

                            PALADIN LABS

                            Canada arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Abaloparatide Acetate

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase III

                            Sponsor : Endo International

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Endo Announces Licensing Agreement for Paladin Labs Inc. to Commercialize Abaloparatide in Canada

                            Details : Endo obtained the rights to abaloparatide-subcutaneous injection and abaloparatide-transdermal patch, a novel formulation and route of administration currently undergoing clinical development. Endo, will be responsible for all commercial activities relat...

                            Brand Name : BA058

                            Molecule Type : Peptide

                            Upfront Cash : Undisclosed

                            January 05, 2021

                            Lead Product(s) : Abaloparatide Acetate

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase III

                            Sponsor : Endo International

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Radius Health

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Radius Health

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Abaloparatide Acetate

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Radius Health: Enrollment Completed for Phase 3 wearABLe Trial

                            Details : The study was designed to look at the effects on bone mineral density of abaloparatide delivered via a novel transdermal device (“abaloparatide-patch”) compared with the current subcutaneous formulation, marketed as TYMLOS®.

                            Brand Name : BA058

                            Molecule Type : Peptide

                            Upfront Cash : Not Applicable

                            September 08, 2020

                            Lead Product(s) : Abaloparatide Acetate

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth